Search Results for "retail"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for retail. Results 201 to 210 of 361 total matches.

Phosphate Binders

   
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006  (Issue 1228)
) from retail pharmacies nationwide available from NDCHealth, a healthcare information services company. 2 ...
Hyperphosphatemia in end-stage renal disease can lead to secondary hyperparathyroidism, renal osteodystrophy, metastatic calcification and cardiovascular mortality. addition to dietary restriction of phosphorus and hemodialysis, drugs that bind phosphates in the gut are usually needed as well. Aluminum hydroxide is no longer recommended for long-term use because of concerns about its toxicity.
Med Lett Drugs Ther. 2006 Feb 13;48(1228):15-6 |  Show IntroductionHide Introduction

A Levalbuterol Metered-Dose Inhaler (Xopenex HFA) for Asthma

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006  (Issue 1230)
, 2006) from retail pharmacies nationwide, available from Wolters Kluwer Health. 3. CFC propellants ...
Levalbuterol, the R-isomer of the beta-2 adrenergic agonist albuterol, is now available in the US as a metered-dose inhaler (Xopenex HFA - Sepracor) for treatment of asthma in patients ≥ 4 years old. Levalbuterol has been available since 1999 in a nebulizer solution for treatment of bronchospasm in patients ≥ 6 years old.1 Outside the US, albuterol is called salbutamol, and levalbuterol is levosalbutamol.
Med Lett Drugs Ther. 2006 Mar 13;48(1230):21-2 |  Show IntroductionHide Introduction

Ranolazine (Ranexa) for Chronic Angina

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 2006  (Issue 1236)
on most recent data (April 30, 2006) from retail pharmacies nationwide available from Wolters Kluwer ...
The FDA has approved the marketing of extended release (ER) ranolazine (Ranexa - CV Therapeutics) for treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs. It should be used in combination with a nitrate, a beta-blocker or the dihydropyridine calcium-channel blocker amlodipine (Norvasc), and appears to be more effective in men. The labeling for ranolazine specifies amlodipine as the calcium-channel blocker of choice because the use of other dihydropyridines with ranolazine has not been studied, and use with diltiazem (Cardizem, and...
Med Lett Drugs Ther. 2006 Jun 5;48(1236):46-7 |  Show IntroductionHide Introduction

A Betamethasone-Calcipotriene Combination for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006  (Issue 1238)
– generic 1. Cost of 60 g based on most recent data (May 31, 2006) from retail pharmacies nationwide ...
Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently approved by the FDA for treatment of psoriasis vulgaris in patients ≥ 18 years old.
Med Lett Drugs Ther. 2006 Jul 3;48(1238):55-6 |  Show IntroductionHide Introduction

Decitabine (Dacogen) for Myelodysplastic Syndromes

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006  (Issue 1247)
(September 30, 2006) from retail pharmacists nationwide available from Wolters Kluwer Health ($424.53/vial ...
Decitabine (Dacogen - MGI Pharma), a pyrimidine nucleoside analog of cytidine, was approved by the FDA as an orphan drug for treatment of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hemopathies that decrease production of normal blood elements (red cells, white cells and platelets) and are associated with a risk of progression to acute leukemia.
Med Lett Drugs Ther. 2006 Nov 6;48(1247):91-2 |  Show IntroductionHide Introduction

Extended-Release Minocycline (Solodyn) for Acne

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 2006  (Issue 1248)
30, 2006) from retail pharmacies nationwide available from Wolters Kluwer Health. 2 ...
The FDA has approved an extended-release formulation of minocycline (Solodyn - Medicis) for once-daily treatment of non-nodular moderate to severe acne.
Med Lett Drugs Ther. 2006 Nov 20;48(1248):95-6 |  Show IntroductionHide Introduction

A Fixed-Dose Combination of Sumatriptan and Naproxen for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008  (Issue 1288)
) from retail pharmacies nationwide available from Wolters Kluwer Health. Prices of generic drugs may vary ...
The FDA has approved an oral, fixed-dose combination (Treximet - GlaxoSmithKline) of the selective serotonin receptor agonist ("triptan") sumatriptan (Imitrex) and the nonsteroidal anti-inflammatory drug (NSAID) naproxen sodium (Anaprox, and others) for acute treatment of migraine attacks.
Med Lett Drugs Ther. 2008 Jun 16;50(1288):45-6 |  Show IntroductionHide Introduction

A Granisetron Patch (Sancuso)

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
according to the most recent data (October 31, 2008) from retail pharmacies nationwide according to Wolters ...
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation (Sancuso - ProStrakan).
Med Lett Drugs Ther. 2008 Dec 15;50(1301):103-0 |  Show IntroductionHide Introduction

Long-Acting Beta-2 Agonists in Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 12, 2009  (Issue 1303)
) from retail pharmacies nationwide available from Wolters Kluwer Health. 2. Only 100/50 is approved ...
Continued use of a long-acting beta-2 agonist for treatment of asthma may cause down-regulation of the beta-2 receptor with loss of the bronchoprotective effect from rescue therapy with a short-acting beta-2 agonist. After a large study (SMART) found an increased risk of asthma-related deaths in patients receiving the long-acting beta-2 agonist salmeterol, a boxed warning was added to the labeling of all medications containing a long-acting beta-2 agonist. Now the FDA has completed a meta-analysis of 110 asthma treatment studies in 60,954 patients taking any of the long-acting beta-2 agonist...
Med Lett Drugs Ther. 2009 Jan 12;51(1303):1-2 |  Show IntroductionHide Introduction

Valproic Acid Delayed Release (Stavzor)

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009  (Issue 1309)
, according to February 2009 data from retail pharmacies nationwide available from Wolters Kluwer Health ...
The FDA has approved a delayed-release capsule formulation of valproic acid (VPA; Stavzor - Noven Therapeutics) for all of the indications for which divalproex sodium (Depakote, and others; Depakote ER) is approved: monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures, and adjunctive therapy in patients with multiple seizure types that include absence seizures; acute treatment of manic episodes associated with bipolar disorder; and prophylaxis of migraine headaches. In addition, valproate (valproic acid or divalproex sodium) is considered a...
Med Lett Drugs Ther. 2009 Apr 6;51(1309):27-8 |  Show IntroductionHide Introduction